AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22236137 — intervention group
Group type: EXPERIMENTAL
Intervention: combined olanzapine-LAI group
Number of subjects: 404
Study 22236137 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404
Study 20028447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer (ANL) applied once every 2 weeks
Number of subjects: 52
Study 20028447 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 52
Study 20028447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer (ANL)
Number of subjects: 52
Study 19192855 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction period attendance
Number of subjects: 111
Study 19192855 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment-based reinforcement of cocaine abstinence
Number of subjects: 111
Study 15999461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 59
Study 15999461 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine
Number of subjects: 59
Study 11313303 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS‐2302
Number of subjects: 75
Study 11313303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9141002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 40 micrograms
Number of subjects: 40
Study 9141002 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine 20 micrograms
Number of subjects: 40
Study 9141002 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐2 administration (500,000 U)
Number of subjects: 40
Study 7951643 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 8
Study 3663463 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 3663463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desethylamiodarone
Number of subjects: 0
Study 3663463 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0
Study 2667437 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 169
Study 2667437 — intervention group
Group type: COMPARATOR
Intervention: Subtotal Gastrectomy (SG)
Number of subjects: 169
Study 31647032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track multidisciplinary treatment (FTMDT) with fast-track perioperative treatment and XELOX adjuvant chemotherapy
Number of subjects: 342
Study 31647032 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with conventional perioperative treatment and mFOLFOX6 adjuvant chemotherapy
Number of subjects: 342
Study 29133641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) in trabeculectomy augmented with Mitomycin C (MMC)
Number of subjects: 40
Study 29133641 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) augmented trabeculectomy (Control group)
Number of subjects: 40
Study 25643024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents discounting money at intake
Number of subjects: 269
Study 25643024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults discounting money at intake
Number of subjects: 269
Study 25643024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults discounting cannabis over treatment
Number of subjects: 269
Study 25643024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents discounting cannabis over treatment
Number of subjects: 269
Study 23594450 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual electroacupuncture
Number of subjects: 86
Study 23594450 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Control)
Number of subjects: 86
Study 21667729 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar plating with locking screws
Number of subjects: 40
Study 21667729 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous K-wire fixation
Number of subjects: 40
Study 19828211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiconazole (200 mg taken once, and 200 mg taken once daily for 2 or 3 days)
Number of subjects: 147
Study 19828211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 17093160 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 5.8 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Number of subjects: 6
Study 17093160 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 7.3 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Number of subjects: 6
Study 17093160 — intervention group
Group type: COMPARATOR
Intervention: Methionine intake of 12.9 mg . kg(‐1) . d(‐1) without dietary cysteine
Number of subjects: 6
Study 17093160 — intervention group
Group type: COMPARATOR
Intervention: Methionine intake of 17.2 mg . kg(‐1) . d(‐1) without dietary cysteine
Number of subjects: 6
Study 17093160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine-sparing effect
Number of subjects: 6
Study 15897725 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive psychosocial relapse‐prevention program + anxiety treatment program (CBT + optional SSRI)
Number of subjects: 96
Study 15897725 — intervention group
Group type: COMPARATOR
Intervention: intensive psychosocial relapse‐prevention program alone
Number of subjects: 96
Study 11529375 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phototherapy
Number of subjects: 80
Study 11529375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phototherapy)
Number of subjects: 80
Study 9663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) iontophoresis
Number of subjects: 0
Study 9663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) iontophoresis
Number of subjects: 0
Study 9663809 — intervention group
Group type: COMPARATOR
Intervention: L-N(G)-monomethyl-arginine (L-NMMA) infusion
Number of subjects: 0
Study 9663809 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline infusion
Number of subjects: 0
Study 9663809 — intervention group
Group type: COMPARATOR
Intervention: Aspirin administration
Number of subjects: 0
Study 7831064 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg tablet bid)
Number of subjects: 44
Study 7831064 — intervention group
Group type: COMPARATOR
Intervention: Mesoglycan (24 mg tablet bid)
Number of subjects: 44
Study 3343933 — intervention group
Group type: EXPERIMENTAL
Intervention: APM-sweetened beverage (10 mg APM/kg body weight per serving)
Number of subjects: 8
Study 3343933 — intervention group
Group type: COMPARATOR
Intervention: Non-sweetened beverage
Number of subjects: 8
Study 31808785 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative frame (news article emphasizing comparative rates of opioid mortality among whites compared to blacks)
Number of subjects: 1549
Study 31808785 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute frame (news article emphasizing absolute rates of opioid mortality among whites)
Number of subjects: 1549
Study 31808785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no news article)
Number of subjects: 1549
Study 30717711 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariable predictors of depression outcome
Number of subjects: 570
Study 30717711 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariable predictors of adverse effects on HADS-D depression score
Number of subjects: 570
Study 30717711 — intervention group
Group type: COMPARATOR
Intervention: Comparison between study arms
Number of subjects: 570
Study 28633089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmab-FOLFOX4
Number of subjects: 77
Study 28633089 — intervention group
Group type: COMPARATOR
Intervention: Pmab-FOLFIRI
Number of subjects: 77
Study 26297704 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking session at 60-75% of heart rate reserve
Number of subjects: 34
Study 26297704 — intervention group
Group type: COMPARATOR
Intervention: Control rest
Number of subjects: 34
Study 24498810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide 40 mg intravenously
Number of subjects: 120
Study 24498810 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.5 mg intravenously
Number of subjects: 120
Study 21258894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drugs for supporting essence and strengthening Pi (SESP)
Number of subjects: 146
Study 21258894 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy + SESP
Number of subjects: 146
Study 21258894 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 146
Study 19692062 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with a loading dose of 0.25% bupivacaine or 0.2% ropivacaine, followed by continuous drip 0.2% ropivacaine
Number of subjects: 45
Study 19692062 — intervention group
Group type: COMPARATOR
Intervention: Nonepidural analgesia with intraoperative morphine and postoperative oxycodone or tramadol plus ibuprofen or paracetamol for 48 hours
Number of subjects: 45
Study 17005508 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 17005508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 17005508 — intervention group
Group type: COMPARATOR
Intervention: No inhaled anaesthetics
Number of subjects: 100
Study 12883662 — intervention group
Group type: EXPERIMENTAL
Intervention: High TS expression
Number of subjects: 229
Study 12883662 — intervention group
Group type: COMPARATOR
Intervention: Low TS expression
Number of subjects: 229
Study 11387782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure of 15 mmHg to 10 mmHg during laparoscopic cholecystectomy
Number of subjects: 0
Study 11387782 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9239455 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular formulation of lornoxicam (8 mg)
Number of subjects: 18
Study 9239455 — intervention group
Group type: COMPARATOR
Intervention: Standard tablets of lornoxicam (8 mg)
Number of subjects: 18
Study 8513660 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pharmacokinetic program for adjusting theophylline infusion rates
Number of subjects: 35
Study 8513660 — intervention group
Group type: COMPARATOR
Intervention: Empiric physician adjustments
Number of subjects: 35
Study 3441775 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0
Study 3441775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29899015 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive arm with personalized step goals and daily feedback for 24 weeks
Number of subjects: 0
Study 29899015 — intervention group
Group type: COMPARATOR
Intervention: Control group received no other interventions
Number of subjects: 0
Study 26519995 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable ultrafiltration (AUF)
Number of subjects: 224
Study 26519995 — intervention group
Group type: COMPARATOR
Intervention: Adjustable intravenous loop diuretics (ALD)
Number of subjects: 224
Study 25516327 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted 24-hour recall
Number of subjects: 110
Study 25516327 — intervention group
Group type: COMPARATOR
Intervention: Written record-assisted method
Number of subjects: 110
Study 25516327 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage screener
Number of subjects: 110
Study 22518376 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional abutment (PA) group
Number of subjects: 28
Study 22518376 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment (DA) group
Number of subjects: 28
Study 22518376 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PA and DA groups
Number of subjects: 28
Study 20070389 — intervention group
Group type: EXPERIMENTAL
Intervention: User-designed Medicaid managed care (MMC) guidebook; 77% of intervention participants reported using the guidebook, with 97.9% finding it somewhat or very useful.
Number of subjects: 692
Study 20070389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guidebook intervention).
Number of subjects: 692
Study 18091257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 38
Study 16274302 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tunnel technique
Number of subjects: 31
Study 16274302 — intervention group
Group type: COMPARATOR
Intervention: Langer and Langer technique
Number of subjects: 31
Study 12372124 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 trimer
Number of subjects: 10
Study 12372124 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 fragments
Number of subjects: 10
Study 12372124 — intervention group
Group type: COMPARATOR
Intervention: rBet v 1 wild-type
Number of subjects: 10
Study 12372124 — intervention group
Group type: COMPARATOR
Intervention: diluent (albumin)
Number of subjects: 10
Study 10449884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 753
Study 10449884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with thrombolytic treatment
Number of subjects: 753
Study 10449884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin without thrombolytic treatment
Number of subjects: 753
Study 8580215 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf)
Number of subjects: 12
Study 8580215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified porcine surfactant (Curosurf)
Number of subjects: 12
Study 8580215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surfactants
Number of subjects: 12
Study 1688487 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of AOAA four times a day for 1 week
Number of subjects: 66
Study 1688487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 318978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg, three times a day for 10 days)
Number of subjects: 100
Study 318978 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (up to 480 mg trimethoprim and 2,400 mg sulphamethoxazole daily for males, two thirds of this dose for females)
Number of subjects: 100
Study 318978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 318978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 100
Study 318978 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 100
Study 30017152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava digital scan
Number of subjects: 10
Study 30017152 — intervention group
Group type: EXPERIMENTAL
Intervention: iTero digital scan
Number of subjects: 10
Study 30017152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec digital scan
Number of subjects: 10
Study 30017152 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 10
Study 28797783 — intervention group
Group type: EXPERIMENTAL
Intervention: tbo-filgrastim (Granix) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Number of subjects: 97
Study 28797783 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (Neupogen) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Number of subjects: 97
Study 28797783 — intervention group
Group type: EXPERIMENTAL
Intervention: tbo-filgrastim (Granix)
Number of subjects: 97
Study 28797783 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (Neupogen)
Number of subjects: 97
Study 26694073 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported leisure time physical activity (LTPA)
Number of subjects: 2367
Study 26694073 — intervention group
Group type: EXPERIMENTAL
Intervention: Slight physical activity up to 4 hours a week in men with IGT
Number of subjects: 2367
Study 26694073 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense physical activity in men with IGT
Number of subjects: 2367
Study 25247957 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiari I malformation patients with transverse sinus stenosis
Number of subjects: 30
Study 25247957 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiari I malformation patients
Number of subjects: 30
Study 25247957 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 22323041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 32
Study 22323041 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (WLC)
Number of subjects: 32
Study 20381664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (64% of patients)
Number of subjects: 1461
Study 20381664 — intervention group
Group type: COMPARATOR
Intervention: Rate control (36% of patients)
Number of subjects: 1461
Study 20381664 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (first prescriptions)
Number of subjects: 1461
Study 20381664 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (second prescriptions)
Number of subjects: 1461
Study 20381664 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 1461
Study 18928074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental illness role-play as part of routine teaching
Number of subjects: 332
Study 18928074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no role-play)
Number of subjects: 332
Study 15982121 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level timing (isochronous tapping)
Number of subjects: 32
Study 15982121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of multiple targets (rhythm production)
Number of subjects: 32
Study 15982121 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection against a dominant rhythm and switching between rhythms
Number of subjects: 32
Study 12056785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% alanyl-glutamine infusion of 0.5 g/kg
Number of subjects: 20
Study 12056785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10491061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling micrografts at 1 degrees C for 5 hours (experimental group B)
Number of subjects: 10
Study 10491061 — intervention group
Group type: COMPARATOR
Intervention: Room temperature preservation at 26 degrees C for 5 hours (control group A)
Number of subjects: 10
Study 8776210 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual Cycle Triggered Training (MCTT)
Number of subjects: 0
Study 8776210 — intervention group
Group type: COMPARATOR
Intervention: Regular Training (RT)
Number of subjects: 0
Study 1730080 — intervention group
Group type: EXPERIMENTAL
Intervention: A + I (cytarabine 100 mg/m2/d + idarubicin 13 mg/m2/d)
Number of subjects: 214
Study 1730080 — intervention group
Group type: COMPARATOR
Intervention: A + D (cytarabine 100 mg/m2/d + daunorubicin 45 mg/m2/d)
Number of subjects: 214
Study 1730080 — intervention group
Group type: EXPERIMENTAL
Intervention: A + I
Number of subjects: 214
Study 1730080 — intervention group
Group type: COMPARATOR
Intervention: A + D
Number of subjects: 214
Study 6085363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg)
Number of subjects: 35
Study 6085363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 35
Study 6085363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 35
Study 6085363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Acebutolol
Number of subjects: 35
Study 30879810 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted alfalfa hay (RAH)
Number of subjects: 20
Study 30879810 — intervention group
Group type: COMPARATOR
Intervention: Dry alfalfa hay (AH)
Number of subjects: 20
Study 29540305 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training at 70% of five repetition maximum (G70)
Number of subjects: 22
Study 29540305 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training at 95% of five repetition maximum (G95)
Number of subjects: 22
Study 27331824 — intervention group
Group type: EXPERIMENTAL
Intervention: l-leucine (LEU)
Number of subjects: 9
Study 27331824 — intervention group
Group type: EXPERIMENTAL
Intervention: ursolic acid (UA)
Number of subjects: 9
Study 27331824 — intervention group
Group type: COMPARATOR
Intervention: cellulose placebo (PLC)
Number of subjects: 9
Study 25238062 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT)
Number of subjects: 14
Study 25238062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 23337636 — intervention group
Group type: EXPERIMENTAL
Intervention: Whites
Number of subjects: 1821
Study 23337636 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 1821
Study 21233772 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 18 weeks
Number of subjects: 0
Study 21233772 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21432578 — intervention group
Group type: EXPERIMENTAL
Intervention: manualized cognitive-behavioural group psychotherapy plus open methylphenidate treatment
Number of subjects: 144
Study 21432578 — intervention group
Group type: COMPARATOR
Intervention: supportive counselling
Number of subjects: 144
Study 17458426 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetirizine dinitrate (4.4 mg twice daily)
Number of subjects: 36
Study 17458426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cetirizine dihydrochloride (10 mg once daily)
Number of subjects: 36
Study 17458426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14694177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (CsA) and sirolimus (SRL); group 1
Number of subjects: 90
Study 14694177 — intervention group
Group type: COMPARATOR
Intervention: Full-dose cyclosporine (CsA) and mycophenolate mofetil; group 2
Number of subjects: 90
Study 11215542 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training with followup support
Number of subjects: 0
Study 11215542 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training without followup support
Number of subjects: 0
Study 11215542 — intervention group
Group type: COMPARATOR
Intervention: Standard after-care treatment (comparison group)
Number of subjects: 0
Study 9510041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole
Number of subjects: 422